Acute Respiratory Distress Syndrome (ARDS) is the most serious complication of coronavirus-induced COVID-19 disease (SARS-CoV2) and is a major challenge for health actors and systems, as illustrated by the recent global pandemic. Among the important characteristics of COVID-19-related ARDS, alveolar epithelial disease and inflammation play a predominant role. Our previous results suggest an essential role of the advanced glycation product receptor (RAGE) in pulmonary epithelial lesions and cytokinic thunderstorm during ARDS. In addition, plasma soluble RAGE (sRAGE) is a marker of pulmonary epithelial lesion correlated with mortality in patients with ARDS. Inhaled sevoflurane is a halogenated anesthetic widely used for general anesthesia and also available for resuscitation sedation. In a pilot clinical study of our group in patients with ARDS, sevoflurane inhalation was associated with improved arterial oxygenation, decreased alveolar and systemic inflammation, and decreased pulmonary epithelial lesions assessed by blood sRAGE levels. This project aims to confirm this analysis thus opening the way to new personalised therapeutic perspectives for serious COVID-19-related lung disease.